Robert C. Scott
Impact in
- Surgery top 0.1%
- Lipoproteins and Cardiovascular Health
- Pharmaceutical Science top 0.5%
Papers in
- Surgery 57
- Lipoproteins and Cardiovascular Health 53
-
- Innovation Policy and R&D 6
- Pharmaceutical Economics and Policy 5
- Co-authors
- Scott M. Wasserman (48 shared papers)Evan A. Stein (10 shared papers)Frederick J. Raal (14 shared papers)Sarah Gould (1 shared paper)Philip A. Horvath (4 shared papers)Michael J. Koren (13 shared papers)Dirk Blom (10 shared papers)Ransi Somaratne (12 shared papers)
- Journals
- Journal of the American College of Cardiology (9 papers)Circulation (8 papers)The Lancet (6 papers)American Heart Journal (3 papers)Journal of clinical lipidology (3 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Robert C. Scott
140 papers receiving 11.3k citations
Robert C. Scott's Hit Papers
Peers
Comparison fields: 5 of 185
- Surgery 7.4k
- Pharmaceutical Science 544
- Endocrinology, Diabetes and Metabolism 1.3k
- Economics and Econometrics 2.2k
- Cancer Research 1.0k
Countries citing papers authored by Robert C. Scott
This map shows the geographic impact of Robert C. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Scott more than expected).
Fields of papers citing papers by Robert C. Scott
This network shows the impact of papers produced by Robert C. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Scott. The network helps show where Robert C. Scott may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert C. Scott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 146 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Hit paper breakdown → | 2015 | 1146 |
| 2 | Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients Hit paper breakdown → | 2016 | 829 |
| 3 | 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review Hit paper breakdown → | 2005 | 645 |
| 4 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 588 |
| 5 | A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia Hit paper breakdown → | 2014 | 583 |
| 6 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 572 |
| 7 | On The Direction of Preference for Moments of Higher Order Than The Variance Hit paper breakdown → | 1980 | 528 |
| 8 | Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance Hit paper breakdown → | 2014 | 434 |
| 9 | Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia Hit paper breakdown → | 2014 | 420 |
| 10 | Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia Hit paper breakdown → | 2012 | 409 |
| 11 | Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients Hit paper breakdown → | 2012 | 375 |
| 12 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Hit paper breakdown → | 2012 | 358 |
| 13 | Anti-PCSK9 Monotherapy for Hypercholesterolemia Hit paper breakdown → | 2014 | 348 |
| 14 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Hit paper breakdown → | 2012 | 300 |
| 15 | Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) Hit paper breakdown → | 2014 | 287 |
| 16 | 2013 | 275 | |
| 17 | 1988 | 186 | |
| 18 | 2013 | 182 | |
| 19 | 2016 | 174 | |
| 20 | 2005 | 162 |
About Robert C. Scott
Robert C. Scott is a scholar working on Surgery, Economics and Econometrics, Computational Mechanics, Aerospace Engineering and Cardiology and Cardiovascular Medicine, having authored 146 papers that have together received 11.7k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (53 papers), Computational Fluid Dynamics and Aerodynamics (11 papers), Aerospace and Aviation Technology (9 papers), Advancements in Transdermal Drug Delivery (8 papers), Innovation Policy and R&D (6 papers), Contact Dermatitis and Allergies (5 papers), Aeroelasticity and Vibration Control (5 papers) and Pharmaceutical Economics and Policy (5 papers). The work is most often cited by research in Surgery (7.4k citations), Pharmaceutical Science (544 citations), Endocrinology, Diabetes and Metabolism (1.3k citations), Economics and Econometrics (2.2k citations) and Cancer Research (1.0k citations). Robert C. Scott has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Scott M. Wasserman, Evan A. Stein, Frederick J. Raal, Sarah Gould, Philip A. Horvath, Michael J. Koren, Dirk Blom, Ransi Somaratne, Robert P. Giugliano and Marc S. Sabatine. Their work appears in journals such as Journal of the American College of Cardiology, Circulation, The Lancet, American Heart Journal and Journal of clinical lipidology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.